Capsule Summary Slidesets

Share

Program Content

Activities

  • COSMIC-021: mCRPC Cohort
    COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 21, 2021

    Expires: September 20, 2022

  • DESTINY-Gastric02
    DESTINY-Gastric02: Trastuzumab Deruxtecan in Western Patients With HER2+ Advanced Gastric or GEJ Cancer With Progression Following First-line Trastuzumab-Containing Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 22, 2021

    Expires: September 21, 2022

  • DESTINY-Breast03
    DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2021

    Expires: September 22, 2022

  • CASPIAN: 3-Yr OS
    CASPIAN: 3-Yr Survival Update of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 23, 2021

  • VESPER
    VESPER: Phase III Trial of Perioperative Chemotherapy With Dose-Dense MVAC vs Gemcitabine + Cisplatin in Patients With Muscle-Invasive Bladder Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2021

    Expires: September 26, 2022

  • PEACE-1: OS in mCSPC
    PEACE-1: Overall Survival With Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2021

    Expires: September 26, 2022

  • DESTINY-Lung01: HER2mut Cohort
    DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 27, 2021

    Expires: September 26, 2022

  • CheckMate 649
    CheckMate 649: Updated Results From Phase III Trial of First-line Nivolumab + CT or Ipilimumab vs CT in Advanced Gastroesophageal Cancers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2021

    Expires: September 27, 2022

  • TULIP
    Phase III TULIP: vic-Trastuzumab Duocarmazine vs Physician’s Choice Treatment in Previously Treated HER2+ Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2021

    Expires: September 27, 2022

  • KEYNOTE-355 Final Results
    KEYNOTE-355: Randomized, Placebo-Controlled Phase III of Pembrolizumab + Chemotherapy in Previously Untreated Metastatic TNBC (Final Results)
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 28, 2021

  • COSMIC-311 Final Analysis
    COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 29, 2021

    Expires: September 28, 2022

  • Abiraterone + ADT in High-Risk M0 PCa
    STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 30, 2021

    Expires: September 29, 2022

  • Dato-DXd in NSCLC With Mutations
    Datopotamab Deruxtecan in Advanced NSCLC With Actionable Genomic Alterations: TROPION-Pan Tumor01 Phase I Trial Subset Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 30, 2021

    Expires: September 29, 2022

  • VISION: HRQoL, Pain, Safety
    VISION: HRQoL, Pain, and Safety Outcomes With 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 30, 2021

    Expires: September 29, 2022

  • EPOCH
    EPOCH: Phase III Trial Comparing Transarterial Radioembolization With Yttrium-90 + Second-line CT vs CT Only in Patients With Unresectable Colorectal Liver Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 01, 2021

    Expires: September 30, 2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc